Get the Stockscreener App
9.50
3.49%
+0.32
After Hours:
9.63
0.13
+1.37%
Astria Therapeutics Inc stock is currently priced at $9.50, with a 24-hour trading volume of 2.82M.
It has seen a +3.49% increased in the last 24 hours and a -29.68% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $9.16 pivot point. If it approaches the $9.59 resistance level, significant changes may occur.
Previous Close:
$9.18
Open:
$9.15
24h Volume:
2.82M
Market Cap:
$521.67M
Revenue:
-
Net Income/Loss:
$-72.89M
P/E Ratio:
-3.8934
EPS:
-2.44
Net Cash Flow:
$-68.47M
1W Performance:
+5.56%
1M Performance:
-29.68%
6M Performance:
+99.58%
1Y Performance:
-30.76%
1D Range:
$9.02
$9.83
52W Range:
$4.26
$16.90
Astria Therapeutics Inc Stock (ATXS) Company Profile
Name
Astria Therapeutics Inc
Sector
Industry
Phone
617 349 1971
Address
100 High Street, 28th Floor, Boston
Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-28-23 | Initiated | Evercore ISI | Outperform |
Astria Therapeutics Inc Stock (ATXS) Latest News
Is Artivion (AORT) Stock Outpacing Its Medical Peers This Year?
Zacks Investment Research
$5.6M Bet On This Real Estate Stock? Check Out These 3 Stocks Insiders Are Buying
Benzinga
Is a Surprise Coming for Astria Therapeutics (ATXS) This Earnings Season?
Zacks Investment Research
Suncor (SU) Q3 Earnings Preview: What Investors Need to Know
Zacks Investment Research
Will NexTier Merger Boost Patterson-UTI's (PTEN) Q3 Earnings?
Zacks Investment Research
Astria Therapeutics Inc Stock (ATXS) Financials Data
Astria Therapeutics Inc (ATXS) Net Income 2024
ATXS net income (TTM) was -$72.89 million for the quarter ending December 31, 2023, a -40.63% decrease year-over-year.
Astria Therapeutics Inc (ATXS) Cash Flow 2024
ATXS recorded a free cash flow (TTM) of -$68.47 million for the quarter ending December 31, 2023, a -56.95% decrease year-over-year.
Astria Therapeutics Inc (ATXS) Earnings per Share 2024
ATXS earnings per share (TTM) was -$2.42 for the quarter ending December 31, 2023, a +33.33% growth year-over-year.
Astria Therapeutics Inc Stock (ATXS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Morabito Christopher | Chief Medical Officer |
Apr 01 '24 |
Sale |
13.59 |
10,000 |
135,939 |
0 |
| PERCEPTIVE ADVISORS LLC | Director |
Feb 01 '24 |
Buy |
12.09 |
2,481,350 |
29,999,522 |
4,873,721 |
| Morabito Christopher | Chief Medical Officer |
Jan 29 '24 |
Option Exercise |
3.87 |
9,200 |
35,604 |
9,200 |
| Morabito Christopher | Chief Medical Officer |
Jan 29 '24 |
Sale |
11.15 |
9,200 |
102,552 |
0 |
| Morabito Christopher | Chief Medical Officer |
Jan 26 '24 |
Option Exercise |
3.87 |
800 |
3,096 |
800 |
| Morabito Christopher | Chief Medical Officer |
Jan 26 '24 |
Sale |
11.02 |
800 |
8,812 |
0 |
| PERCEPTIVE ADVISORS LLC | Director |
Dec 21 '23 |
Buy |
6.20 |
740,000 |
4,588,000 |
2,392,371 |
| PERCEPTIVE ADVISORS LLC | Director |
Oct 16 '23 |
Buy |
6.51 |
1,074,608 |
6,999,997 |
1,652,371 |
About Astria Therapeutics Inc
Astria Therapeutics, Inc., a biopharmaceutical company, engages in developing therapies for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-021, a monoclonal antibody inhibitor of plasma kallikrein that is in preclinical development stage for the treatment of hereditary angioedema, a rare genetic disorder causing swelling in the face, limbs, abdomen, and airway. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
3.18%
Cap:
|
Volume (24h):